 |
|
Effect of Orlistat on Weight and Body Composition in Obese Adolescents
A Randomized Controlled Trial
Jean-Pierre Chanoine, MD, PhD;
Sarah Hampl, MD, FAAP;
Craig Jensen, MD;
Mark Boldrin, MS;
Jonathan Hauptman, MD
JAMA. 2005;293:2873-2883.
Context The prevalence of overweight and obesity in children and adolescents is increasing rapidly. In this population, behavioral therapy alone has had limited success in providing meaningful, sustained weight reduction, and pharmacological treatment has not been extensively studied.
Objective To determine the efficacy and safety of orlistat in weight management of adolescents.
Design, Setting, and Patients Multicenter, 54-week (August 2000-October 2002), randomized, double-blind study of 539 obese adolescents (aged 12-16 years; body mass index [BMI]  2 units above the 95th percentile) at 32 centers in the United States and Canada.
Interventions A 120-mg dose of orlistat (n = 357) or placebo (n = 182) 3 times daily for 1 year, plus a mildly hypocaloric diet (30% fat calories), exercise, and behavioral therapy.
Main Outcome Measures Change in BMI; secondary measures included changes in waist and hip circumference, weight loss, lipid measurements, and glucose and insulin responses to oral glucose challenge.
Results There was a decrease in BMI in both treatment groups up to week 12, thereafter stabilizing with orlistat but increasing beyond baseline with placebo. At the end of the study, BMI had decreased by 0.55 with orlistat but increased by 0.31 with placebo (P = .001). Compared with 15.7% of the placebo group, 26.5% of participants taking orlistat had a 5% or higher decrease in BMI (P = .005); 4.5% and 13.3%, respectively, had a 10% or higher decrease in BMI (P = .002). At study end, weight had increased 0.53 kg with orlistat and 3.14 kg with placebo (P<.001). Dual-energy x-ray absorptiometry showed that this difference was explained by changes in fat mass. Waist circumference decreased in the orlistat group but increased in the placebo group (–1.33 cm vs +0.12 cm; P<.05). Generally mild to moderate gastrointestinal tract adverse events occurred in 9% to 50% of the orlistat group and in 1% to 13% of the placebo group.
Conclusions In combination with diet, exercise, and behavioral modification, orlistat statistically significantly improved weight management in obese adolescents compared with placebo. The use of orlistat for 1 year in this adolescent population did not raise major safety issues although gastrointestinal adverse events were more common in the orlistat group.
Author Affiliations: Endocrinology and Diabetes Unit, British Columbia Children’s Hospital, Vancouver (Dr Chanoine); Children’s Mercy Hospitals and Clinics, Kansas City, Mo (Dr Hampl); Department of Medicine, Baylor College of Medicine, Houston, Tex (Dr Jensen); and Hoffmann-La Roche Inc, Nutley, NJ (Mr Boldrin and Dr Hauptman).
RELATED ARTICLE
Pharmacotherapy for Adolescent Obesity: A Weighty Issue
Alain Joffe
JAMA. 2005;293(23):2932-2934.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Type 2 diabetes in childhood: epidemiological and clinical aspects
Matyka
Br Med Bull 2008;86:59-75.
ABSTRACT
| FULL TEXT
Is there a place for bariatric surgery in treating childhood obesity?
Shield et al.
Arch. Dis. Child. 2008;93:369-372.
FULL TEXT
Treatment Modalities of Obesity: What fits whom?
Hainer et al.
Diabetes Care 2008;31:S269-S277.
ABSTRACT
| FULL TEXT
Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report
Barlow and and the Expert Committee
Pediatrics 2007;120:S164-S192.
ABSTRACT
| FULL TEXT
Recommendations for Treatment of Child and Adolescent Overweight and Obesity
Spear et al.
Pediatrics 2007;120:S254-S288.
ABSTRACT
| FULL TEXT
State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant
Dunican et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:367-388.
ABSTRACT
Pharmacotherapeutic Options for Overweight Adolescents
Dunican et al.
The Annals of Pharmacotherapy 2007;41:1445-1455.
ABSTRACT
| FULL TEXT
Pharmacological Treatment of the Overweight Patient
Bray and Greenway
Pharmacol. Rev. 2007;59:151-184.
FULL TEXT
Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach
Freemark
Diabetes Care 2007;30:395-402.
FULL TEXT
Tackling the obesity epidemic: new approaches.
Reilly
Arch. Dis. Child. 2006;91:724-726.
FULL TEXT
Weight-Loss Drugs Appropriate for Some Morbidly Obese Teens
Beckley
DOC News 2006;3:9-9.
FULL TEXT
Obesity in childhood and adolescence: evidence based clinical and public health perspectives.
Reilly
Postgrad. Med. J. 2006;82:429-437.
ABSTRACT
| FULL TEXT
Other articles noted
Evid. Based Med. 2006;11:31-32.
FULL TEXT
The regulation of appetite
Druce and Bloom
Arch. Dis. Child. 2006;91:183-187.
ABSTRACT
| FULL TEXT
Journal Watch
Arch. Dis. Child. 2005;90:1200-1201.
FULL TEXT
Lucina
Arch. Dis. Child. 2005;90:1210-1210.
FULL TEXT
Current and Future Treatment of Metabolic Syndrome and Type 2 Diabetes in Children and Adolescents
Mallare et al.
Diabetes Spectr. 2005;18:220-228.
ABSTRACT
| FULL TEXT
Orlistat Helps Manage Weight in Teens
DOC News 2005;2:13-13.
FULL TEXT
2nd International Symposium on Triglycerides and HDL: Metabolic syndrome
Bloomgarden
Diabetes Care 2005;28:2577-2584.
FULL TEXT
Juvenile Obesity: Is School-Based Enhanced Physical Activity Relevant?
Bar-Or
Arch Pediatr Adolesc Med 2005;159:996-997.
FULL TEXT
Orlistat for Obese Teens?
Journal Watch Cardiology 2005;2005:1-1.
FULL TEXT
Orlistat Aids Weight Management in Adolescents
JWatch Pediatrics 2005;2005:2-2.
FULL TEXT
Orlistat and Weight Loss in Adolescents
JWatch General 2005;2005:1-1.
FULL TEXT
What's new in the other general journals
Tonks
BMJ 2005;330:1469-1470.
FULL TEXT
Pharmacotherapy for Adolescent Obesity: A Weighty Issue
Joffe
JAMA 2005;293:2932-2934.
FULL TEXT
|
